A case of favorable response after combination treatment with interferon-α and cyclooxygenase-2 inhibitor against metastatic renal cell carcinoma

Acta Urologica Japonica

Volumn 58, Issue 1, 2012, Pages 25-29

  Onishi, Tetsuro ^a   Suzuki, Hiroyoshi ^b   Igarashi, Tatsuo ^c  

^a Department of Urology   (Japan)

^b TOHO UNIVERSITY   (Japan)

^c CHIBA UNIVERSITY   (Japan)

Author keywords

Combination treatment with ifn ; Cyclooxygenase 2 inhibitor; Renal cell carcinoma

Indexed keywords

ALPHA INTERFERON; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; IMMUNOLOGIC FACTOR; PYRAZOLE DERIVATIVE; SULFONAMIDE;

AGED; CASE REPORT; DRUG COMBINATION; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MALE; MEDIASTINUM TUMOR; METASTASIS; PATHOLOGY; REVIEW;

AGED; CARCINOMA, RENAL CELL; CYCLOOXYGENASE 2 INHIBITORS; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MALE; MEDIASTINAL NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84863401841     PISSN: 00181994     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Motzer RJ, Houtson TE, Tomezak P, et al. : Overall survival and update results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590, 2009
2. Bukowski RM : Cytokine therapy for metastatic renal cell carcinoma. Semin Urol 19: 148-154, 2001
3. Koehne CH and Dubois RN : Cox-2 inhibition and colorectal cancer. Semin Oncol 31: 12-21, 2004 (Pubitemid 38879410)
4. Rini BI, Weinberg V, Dunlap S, et al : Maximal Cox2 immunostaining and clinical response to celecoxib and interferon-alpha therapy in metastatic renal cell carcinoma. Cancer 106: 566-575, 2006 (Pubitemid 43157619)
5. Shinohara N, Kumagai A, Kanagawa K, et al. : Multicenter phase II trial of combination therapy with meloxican, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn J Clin Oncol 39: 720-726, 2009
6. Feng Y, Papavassiliou ED, Arvind P, et al. : The effect of eicosanoids on the expression of MHC genes in cultured human colon cancer cells and mouse colonocytes in vivo. Prostaglandins Leukot Essent Fatty Acids 56: 373-378, 1996 (Pubitemid 27014124)
7. Della Bella S, Molteni M, Compasso S, et al.: Different effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes. Prostaglandins Leukot Essent Fatty Acids 56: 177-184, 1997 (Pubitemid 27130389)
8. Yang L, Yamagata N, Yadav R, et al. : Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111 : 727-735, 2004
9. Stolina M, Sharma S, Lin Y, et al. : Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J Immunol 164:361-370,2000 (Pubitemid 30013010)
10. Onishi T, Ohishi Y, Imagawa K, et al. : An assessment of the immunological environment based on intratumoral cytokine production in renal cell carcinoma. Br J Urol 83: 488-492, 1999 (Pubitemid 29151178)
11. Irie T, Tsujii M, Tsuji S, et al. : Synergistic antitumor effects of celccoxib with 5-fluorouracil dependent on IFN-γ. Int J Cancer 121: 878-883, 2007 (Pubitemid 47106220)
12. Komai T, Saito K, Sakai K, et al.: Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int 99: 77-80, 2007 (Pubitemid 44915624)